Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
For Laboratory and Research Purposes Only Not for human consumption or therapeutic use
Patients with diabetes already face elevated pancreatitis risk due to obesity, hypertriglyceridemia, and metabolic syndromeconditions common among those prescribed GLP-1 medications
Retatrutide is an investigational pharmaceutical agent currently under clinical development and does not hold a marketing authorisation from the MHRA or the European Medicines Agency (EMA)
This is a common concern regardless of what other medications are in the picture
US$ 22.95
US$ 24.80
US$ 24.16
